Read by QxMD icon Read

Bone Marrow Transplantation

Guillermo Ortí, Irene García-Cadenas, Lucia López-Corral, Ariadna Pérez, Maria Jose Jimenez, Isabel Sánchez-Ortega, Laura Alonso, Luisa Sisinni, Laura Fox, Guillermo Villacampa, Isabel Badell, Cristina Diaz de Heredia, Rocio Parody, Christelle Ferrà, Carlos Solano, Dolores Caballero, Rodrigo Martino, Sergi Querol, David Valcárcel
In the original version of this article, author 'Lucia López-Corral' was incorrectly listed as 'Lucia López'. This has now been corrected in both the PDF and HTML versions of the article to 'Lucia López-Corral'.
February 7, 2019: Bone Marrow Transplantation
Jakob R Passweg, Helen Baldomero, Grzegorz W Basak, Christian Chabannon, Selim Corbacioglu, Rafael Duarte, Jürgen Kuball, Arjan Lankester, Silvia Montoto, Régis Peffault de Latour, John A Snowden, Jan Styczynski, Ibrahim Yakoub-Agha, Mutlu Arat, Mohamad Mohty, Nicolaus Kröger
Hematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants done in Europe and associated countries continues to rise with 45,418 HCT in 41,100 patients [(17,155 allogeneic (42%) and 23,945 autologous (58%)] reported by 683 centers in 50 countries in 2017. Main indications were myeloid malignancies 10,147 (25%; 96% allogeneic), lymphoid malignancies 26,488 (64%; 19% allogeneic), solid tumors 1,607 (3.9%; 2% allogeneic), and nonmalignant disorders 2,667 (7%; 81% allogeneic)...
February 6, 2019: Bone Marrow Transplantation
Ahmed Gaballa, Arwen Stikvoort, Björn Önfelt, Jonas Mattsson, Mikael Sundin, Emma Watz, Michael Uhlin
The impact of intra-graft T cells on the clinical outcome after allogeneic hematopoietic cell transplantation has been investigated. Most previous studies have focused on the role of αβ cells while γδ cells have received less attention. It has been an open question whether γδ cells are beneficial or not for patient outcome, especially with regards to graft versus host disease. In this study, graft composition of γδ cell subsets was analyzed and correlated to clinical outcome in 105 recipients who underwent allogeneic hematopoietic cell transplantation between 2013 and 2016...
February 5, 2019: Bone Marrow Transplantation
Hidehiro Itonaga, Ken Ishiyama, Kazunari Aoki, Jun Aoki, Takayuki Ishikawa, Kazuteru Ohashi, Takayuki Fukuda, Yukiyasu Ozawa, Shuichi Ota, Naoyuki Uchida, Tetsuya Eto, Koji Iwato, Yuju Ohno, Minoko Takanashi, Tatsuo Ichinohe, Yoshiko Atsuta, Yasushi Miyazaki
We conducted a nationwide retrospective study to evaluate the prognostic influence of +1, der(1;7)(q10;p10) [hereafter der(1;7)] and -7/del(7q) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for de novo myelodysplastic syndromes (MDS). In this database, 69 MDS patients with der(1;7), 75 with -7/del(7q), and 511 with normal karyotype (NK) underwent allo-HSCT at advanced disease status. The 3-year overall survival (OS) and cumulative incidence of relapse (CIR) were 50.4 and 19.4% for those with der(1;7), 36...
February 4, 2019: Bone Marrow Transplantation
Jan-Erik Johansson, John Bratel, Mats Hardling, Lena Heikki, Ulf-Henrik Mellqvist, Bengt Hasséus
The conditioning therapy used in connection with haematopoietic stem cell transplantation (HSCT) can induce painful oral mucositis, which has negative impacts on patient quality of life and survival, as well as on health-care costs. While cooling of the oral mucosa (cryotherapy) is regarded as standard prophylaxis against oral mucositis, the long duration of the treatment affects compliance owing to side effects. In this prospective, randomised trial, 94 patients (62 males/32 females; median age 59 years, range 34-69) with a diagnosis of myeloma who were undergoing autologous HSCT were randomised 1:1 to receive cryotherapy for 7 h (N = 46) or 2 h (N = 48)...
February 4, 2019: Bone Marrow Transplantation
Henrik Sengeløv, Peter M Petersen, Lotte Fog, Mette Schmidt, Lena Specht
No abstract text is available yet for this article.
February 4, 2019: Bone Marrow Transplantation
Yasuhiro Okamoto, Kazuko Kudo, Ken Tabuchi, Daisuke Tomizawa, Takashi Taga, Hiroaki Goto, Hiromasa Yabe, Yozo Nakazawa, Katsuyoshi Koh, Kazuhiro Ikegame, Nao Yoshida, Naoyuki Uchida, Kenichiro Watanabe, Yuuki Koga, Masami Inoue, Koji Kato, Yoshiko Atsuta, Hiroyuki Ishida
Allogeneic hematopoietic stem cell transplantation (HSCT) can be used to treat children with refractory acute myeloid leukemia (AML). This retrospective analysis aimed to describe the outcomes and risk factors in such children. Data were collected through the nation-wide registry program in Japan. A total of 417 AML (median age: 13 years) patients 20 years or younger at HSCT, between January 2001 and December 2015, were included. A total of 314 patients died, and the median follow-up duration of the survivors was 1052 days...
February 4, 2019: Bone Marrow Transplantation
L Farnault, G Venton, B Pourroy, N Jourde-Chiche, V Ivanov, R Arcani, P Roche, C Mercier, J Colle, R Fanciullino, R T Costello
No abstract text is available yet for this article.
February 4, 2019: Bone Marrow Transplantation
Giorgia Battipaglia, Ariane Boumendil, Myriam Labopin, Fabio Ciceri, Johanna Tischer, Matthias Stelljes, Gerhard Ehninger, Dietrich Beelen, Jürgen Finke, Maria Teresa Van Lint, Matthias Eder, Boris Afanasyev, Renato Fanin, Mohamad Mohty, Annalisa Ruggeri, Arnon Nagler
Refractory or relapsed acute myeloid leukemia (R/R-AML) has poor prognosis. Allogeneic hematopoietic stem-cell transplantation (HSCT) may provide cure in this scenario. We compared outcomes of HSCT from HLA-identical (HLA-id, n = 1654) sibling or haploidentical (Haplo, n = 389) donors in patients with R/R-AML, performed during the period 2007-2015. The Haplo group included patients receiving an unmanipulated graft (post-transplant cyclophosphamide, n = 278; in vivo T-cell depletion, n = 95; or both, n = 16)...
February 4, 2019: Bone Marrow Transplantation
Sara Singer, Nidhi Sharma, Robert Dean, Qiuhong Zhao, Donna Abounader, Patrick Elder, Craig C Hofmeister, Don M Benson, Ashley Rosko, Sam Penza, Leslie Andritsos, Sumithira Vasu, Samantha Jaglowski, Basem M William, Brian Bolwell, Brad Pohlman, Matt Kalaycio, Deepa Jagadeesh, Brian Hill, Ronald Sobecks, Steven M Devine, Navneet S Majhail, Yvonne A Efebera
High-dose chemotherapy followed by autologous hematopoietic cell transplantation (AHCT) is an effective salvage therapy for patients with relapsed chemosensitive non-Hodgkin's lymphoma (NHL). However, the optimal conditioning regimen is unclear. Different conditioning regimens prior to AHCT have been used with the two most common being BEAM (carmustine, etoposide, cytarabine, and melphalan) and BUCYVP16 (busulfan, cyclophosphamide, and etoposide). We sought to compare the two regimens for patients with relapsed NHL undergoing AHCT...
February 4, 2019: Bone Marrow Transplantation
Shaun McCann
No abstract text is available yet for this article.
February 4, 2019: Bone Marrow Transplantation
Yuan-Yuan Zhang, Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Yu-Qian Sun, Kai-Yan Liu, Xiao-Jun Huang
Acute myelogenous leukemia (AML) patients with fetal liver tyrosine kinase 3 (FLT3) internal tandem duplications (ITDs) have poor prognoses if treated with chemotherapy only, primarily as they experience increased relapse rates. To determine whether this alteration also affects outcomes after haploidentical donor (HID) allogeneic hematopoietic stem cell transplantation (allo-HSCT), we compared 334 consecutive FLT3-ITD-positive vs -negative patients with AML (other than acute promyelocytic leukemia) who underwent HID-HSCT...
February 1, 2019: Bone Marrow Transplantation
Helen Jessop, Dominique Farge, Riccardo Saccardi, Tobias Alexander, Montserrat Rovira, Basil Sharrack, Raffaella Greco, Nico Wulffraat, John Moore, Majid Kazmi, Manuela Badoglio, Gillian Adams, Bregje Verhoeven, John Murray, John A Snowden
Over the last 20 years, haematopoietic stem cell transplantation (HSCT) has been used to treat patients with severe autoimmune and inflammatory diseases whose response to standard treatment options has been limited, resulting in a poor long-term prognosis in terms of survival or disability. The vast majority of patients have received autologous HSCT where an increasing evidence-base supports its use in a wide range of autoimmune diseases, particularly relapsing remitting MS, systemic sclerosis and Crohn's disease...
January 31, 2019: Bone Marrow Transplantation
Stefanie W Benoit, Bradley P Dixon, Stuart L Goldstein, Michael R Bennett, Adam Lane, Dana T Lounder, Seth J Rotz, Nicholas J Gloude, Kelly E Lake, Bridget Litts, Stella M Davies
Acute kidney injury (AKI) is a common complication in pediatric hematopoietic stem cell transplantation (HSCT). Serum creatinine is an imprecise biomarker of AKI. We hypothesized that combining creatinine with serum cystatin C (cysC) and urinary neutrophil gelatinase-associated lipocalin (NGAL) more effectively characterizes AKI during the first 28 days of HSCT and better identifies patients at risk of adverse outcomes than creatinine alone. We prospectively assessed the type and severity of AKI in 80 consecutive allogeneic HSCT patients using weekly creatinine, cysC, and NGAL...
January 30, 2019: Bone Marrow Transplantation
Khadega A Abuelgasim, Mohsen Alzahrani, Yousef Alsharhan, Moataz Khairi, Mohammed Hommady, Giamal Gmati, Hind Salama, Osama Ali, Bader Alahmari, Emad M Masuadi, Ahmed Alaskar, Ayman Alhejazi, Moussab Damlaj
No abstract text is available yet for this article.
January 30, 2019: Bone Marrow Transplantation
Hélène A Poirel, Marijke Vanspauwen, Gilles Macq, Anke De Geyndt, Johan Maertens, Evelyne Willems, Dominik Selleslag, Xavier Poiré, Koen Theunissen, Carlos Graux, Tessa Kerre, Pierre Zachée, Nathalie Meuleman, Ann De Becker, Anke Verlinden, Florence Van Obbergh, Christine Schuermans, Virginie De Wilde, Aurélie Jaspers, Delphine Pranger, Dries Deeren, Ivan Van Riet, Evelien Vaes, Yves Beguin
While performance since the introduction of the JACIE quality management system has been shown to be improved for allogeneic hematopoietic stem cell transplants (HSCT), impact on autologous-HSCT remains unclear in Europe. Our study on 2697 autologous-HSCT performed in adults in 17 Belgian centres (2007-2013) aims at comparing the adjusted 1 and 3-yr survival between the different centres & investigating the impact of 3 centre-related factors on performance (time between JACIE accreditation achievement by the centre and the considered transplant, centre activity volume and type of HSCT performed by centres: exclusively autologous vs both autologous & allogeneic)...
January 29, 2019: Bone Marrow Transplantation
Sanghee Hong, Lisa Rybicki, Donna Corrigan, Jane Dabney, Betty K Hamilton, Matt Kalaycio, Christine Lawrence, Linda McLellan, Ronald Sobecks, Stephanie J Lee, Navneet S Majhail
Psychosocial Assessment of Candidates for Transplant (PACT) is a tool originally developed to address psychosocial risks in solid organ transplant recipients and has the potential for application to hematopoietic cell transplantation (HCT) recipients. In a retrospective cohort study, we reviewed 404 adult allogeneic HCT cases from 2003 to 2014 to identify predictors of adverse psychosocial status as determined by PACT. Final PACT rating was poor/borderline (score 0-1) in 5%, acceptable (score 2) in 22%, good (score 3) in 44%, and excellent (score 4) in 29% recipients...
January 29, 2019: Bone Marrow Transplantation
Maheen Z Abidi, Parameswaran Hari, Min Chen, Soyoung Kim, Minoo Battiwala, Parastoo Bahrami Dahi, Miguel Angel Diaz, Robert Peter Gale, Siddhartha Ganguly, Usama Gergis, Jaime Green, Gerhard Hildebrandt, Joshua A Hill, Krishna Komanduri, Hillard Lazarus, David Marks, Taiga Nishihori, Richard Olsson, Sachiko Seo, Celalettin Ustun, Jean Yared, Dwight Yin, John Wingard, Baldeep Mona Wirk, Jeffrey Auletta, Caroline Lindemans, Marcie Riches
Limited data exist on characteristics of central nervous system viruses (CNS-V) in allogeneic hematopoietic stem cell transplant (HCT) recipients. Between 2007 and 2015, the Center for International Blood and Marrow Transplant Research (CIBMTR) received information on 27,532 patients undergoing HCT. Of these, centers reported 165 HCT recipients with CNS-V detected in cerebrospinal fluid within 6 months after HCT. CNS viruses predominantly included human herpes virus 6 (HHV-6) (73%), followed by Epstein-Barr Virus (10%), cytomegalovirus (3%), varicella zoster virus (3%), herpes simplex virus (3%) and Adenovirus (3%)...
January 29, 2019: Bone Marrow Transplantation
Marte B Kammersgaard, Katrine Kielsen, Carsten Heilmann, Marianne Ifversen, Klaus Müller
Sinusoidal obstruction syndrome (SOS) is a potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation (HSCT). We assessed the proposed pediatric EBMT criteria along with the Baltimore and modified Seattle criteria in a population-based cohort. Eighty-seven children (1.1-17.3 years) undergoing myeloablative HSCT from 2010 to 2017 were consecutively included at the Danish National Transplantation Center. In total, 39 (44.8%) patients fulfilled the EBMT criteria and 30 patients (35%) fulfilled the criteria for severe or very severe SOS...
January 25, 2019: Bone Marrow Transplantation
Qi Wen, Yuan Kong, Hong-Yan Zhao, Yuan-Yuan Zhang, Ting-Ting Han, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang
Macrophages (MΦs) are an important immune cell population that are essential for tissue homeostasis and disease pathogenesis. MΦs are now classified as either M1, which produce pro-inflammatory cytokines, or M2, which produce antiinflammatory cytokines. The impact of granulocyte colony-stimulating factor (G-CSF) on MΦs in humans is unclear. Moreover, little is known about the association between MΦ subsets in allografts and the occurrence of acute graft-versus-host disease (aGVHD) in patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT)...
January 25, 2019: Bone Marrow Transplantation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"